Galena Biopharma: DoD To Provide Funding Towards New Clinical Trial With NeuVax

(RTTNews) - Biopharmaceutical company Galena Biopharma (GALE) said the Department of Defense would provide funding towards a new clinical trial with NeuVax to prevent breast cancer recurrence in high-risk HER2 3+ patients.

The grant, a Breast Cancer Research Program or BCRP Breakthrough Award, was obtained by Elizabeth Mittendorf, Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center who will oversee the investigator-sponsored trial.

Galena will support the trial with study drug and funding and will have access to the research to support ongoing registrational studies.

The protocol for the multi-center, prospective, randomized, single-blinded Phase 2 trial is being finalized. It is expected to enroll approximately 100 patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence.

The grant was awarded through the Congressionally Directed Medical Research Program, funded through the Department of Defense, via annual Congressional legislation known as the Defense Appropriations Act.